Success Metrics

Clinical Success Rate
40.0%

Based on 4 completed trials

Completion Rate
40%(4/10)
Active Trials
1(5%)
Results Posted
150%(6 trials)
Terminated
6(29%)

Phase Distribution

Ph phase_3
3
14%
Ph not_applicable
2
10%
Ph phase_2
8
38%
Ph phase_4
3
14%
Ph early_phase_1
3
14%
Ph phase_1
1
5%

Phase Distribution

4

Early Stage

8

Mid Stage

6

Late Stage

Phase Distribution20 total trials
Early Phase 1First-in-human
3(15.0%)
Phase 1Safety & dosage
1(5.0%)
Phase 2Efficacy & side effects
8(40.0%)
Phase 3Large-scale testing
3(15.0%)
Phase 4Post-market surveillance
3(15.0%)
N/ANon-phased studies
2(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

30.8%

4 of 13 finished

Non-Completion Rate

69.2%

9 ended early

Currently Active

1

trials recruiting

Total Trials

21

all time

Status Distribution
Active(2)
Completed(4)
Terminated(9)
Other(6)

Detailed Status

Terminated6
unknown4
Completed4
Withdrawn3
Suspended2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
1
Success Rate
40.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (15.0%)
Phase 11 (5.0%)
Phase 28 (40.0%)
Phase 33 (15.0%)
Phase 43 (15.0%)
N/A2 (10.0%)

Trials by Status

suspended210%
recruiting15%
terminated629%
unknown419%
withdrawn314%
enrolling_by_invitation15%
completed419%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT04911816Phase 1

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

Recruiting
NCT02615938Phase 2

Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)

Terminated
NCT04007562

Acute Rhabdomyolysis and Muscle Pain Associated With Mutations in the LPIN1 Gene - A Retrospective Study Describing the Safety and Efficacy of Hydroxychloroquine Sulfate Given on a Compassionate Basis to Patients Suffering From Lipin-1 Deficiency

Withdrawn
NCT04386057Phase 2

LY3214996 +/- HCQ in Pancreatic Cancer

Completed
NCT06519617Phase 2

Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular Damage

Enrolling By Invitation
NCT04341727Phase 3

Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

Terminated
NCT04336332Phase 2

Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19

Terminated
NCT04329572Early Phase 1

Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19

Suspended
NCT04348474Early Phase 1

Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19

Suspended
NCT04354428Phase 2

Treatment for COVID-19 in High-Risk Adult Outpatients

Terminated
NCT04328961Phase 2

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

Completed
NCT04380818Not Applicable

Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19

Unknown
NCT04340349Early Phase 1

Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals

Unknown
NCT04342221Phase 3

Hydroxychloroquine for COVID-19

Terminated
NCT04361461Phase 3

Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)

Withdrawn
NCT04316377Phase 4

Norwegian Coronavirus Disease 2019 Study

Unknown
NCT04371926Not Applicable

Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk

Withdrawn
NCT04307693Phase 2

Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)

Terminated
NCT02942381Phase 2

A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy

Completed
NCT02765594Phase 4

Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
21